Cancer of the Prostate Clinical Trial
— FALCONOfficial title:
A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment
NCT number | NCT02578940 |
Other study ID # | BED-004 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | November 2015 |
Est. completion date | June 22, 2018 |
Verified date | September 2019 |
Source | Blue Earth Diagnostics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being considered for salvage treatment with the intention of providing disease cure. Also, this study will consolidate the information regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively followed patients at several centres in the UK and assess the effect of PSA level on the likelihood of detecting cancer lesions by 18F-fluciclovine
Status | Completed |
Enrollment | 104 |
Est. completion date | June 22, 2018 |
Est. primary completion date | May 17, 2017 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The subject has had an original diagnosis of PCa and underwent radical curative therapy at least 3 months before enrolment, and has been diagnosed with biochemical recurrence (BCR) on the basis of: 1. Post radical radiotherapy (RRT) / brachytherapy: Increase in PSA level =2.0 ng/mL above the nadir level after radiotherapy (RT) or brachytherapy (ASTRO-Phoenix criteria) [53], or 2. Post radical prostatectomy (RP): EITHER two consecutive rises in PSA and final PSA >0.1ng/ml OR three consecutive rises in PSA., This definition is also applicable to subjects with PSA persistence post RP (where the PSA fails to fall to undetectable levels). i. In addition, the subject post RP, should have a PSA doubling time of =15 months OR PSA level =1.0 ng/mL at time of recruitment. The PSA doubling time will be calculated using the Memorial Sloan Kettering Cancer Center nomogram (http://www.mskcc.org/nomograms/prostate/psa-doubling-time), based on a minimum of two PSA levels within 12 months of screening, taken after the last recorded nadir PSA available at time of screening. - The subject has not had previous recurrences of PCa, i.e. this is the first diagnosis of BCR. - The subject is being considered for radical salvage therapy. - The subject is able and willing to comply with study procedures, and signed, dated and timed informed consent is obtained before any study-related procedure is performed. - The subject's Eastern Cooperative Oncology Group [ECOG] performance status 0-2. - The subject should not have received androgen-deprivation therapy within 3 months of screening. - The subject has a normal or clinically acceptable medical history and vital signs findings at screening (up to 14 days before administration of study drug). Exclusion Criteria: - The subject has been previously included in this study. - The subject has received, or is scheduled to receive, another investigational medicinal product (IMP) from 1 month before to 1 week after administration of fluciclovine (18F) injection. - The subject has known hypersensitivity to fluciclovine (18F) injection or any of its constituents. - The subject has had a choline PET/CT scan within 3 months of the screening visit. - The subject has bilateral hip prostheses. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Greater Glasgow & Clyde NHS Trust | Glasgow | |
United Kingdom | St James Institute of Oncology | Leeds | Yorkshire |
United Kingdom | St Thomas' Hospital | London | |
United Kingdom | University College London Hospital | London | |
United Kingdom | Mount Vernon Cancer Centre, Mount Vernon Hospital | Northwood | Middlesex |
United Kingdom | Churchill Hospital | Oxford | Oxfordshire |
United Kingdom | Royal Marsden Hospital | Sutton | Surrey |
Lead Sponsor | Collaborator |
---|---|
Blue Earth Diagnostics | IND 2 Results LLC, Innovate UK, Syne Qua Non Limited |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact on Patient Treatment /Management | The record of the revised management plan post fluciclovine (18F) PET/CT scan in comparison to the pre-scan intended management plan. | 1 month | |
Secondary | Response Rate to Radical Salvage Therapy | To establish the proportion of patients who have a sustained response to radical salvage therapy. | 7 months | |
Secondary | PSA Threshold for Positive Lesion Detection by 18F Fluciclovine PET/CT in BCR | PSA levels in relation to scan positivity were analysed to determine the optimal PSA threshold for detecting recurrent prostate cancer by 18F fluciclovine PET/CT | 1 month | |
Secondary | Safety of 18F Fluciclovine Injection in Patients Undergoing PET/CT. | Safety was assessed from data on the occurrence of adverse events (AEs) and changes in clinical laboratory tests, vital signs, injection-site status and physical examination findings from the time of administration of 18F fluciclovine injection throughout the study period. | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03653819 -
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
|
N/A | |
Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06363266 -
A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers
|
N/A | |
Active, not recruiting |
NCT02003924 -
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
|
Phase 3 | |
Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
Completed |
NCT00844792 -
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 | |
Completed |
NCT04057859 -
PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training
|
||
Completed |
NCT00564928 -
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT02958787 -
Vessel Sparing Prostate Radiation Therapy
|
Phase 2 | |
Completed |
NCT01897207 -
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05241236 -
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
|
||
Active, not recruiting |
NCT03939689 -
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
|
Phase 2 | |
Completed |
NCT02274350 -
The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects
|
N/A | |
Completed |
NCT00744549 -
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
|
Phase 2 | |
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02212548 -
Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose
|
N/A | |
Completed |
NCT04017325 -
European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up
|
||
Active, not recruiting |
NCT03238170 -
MR-simulation in Radiotherapy for Prostate Cancer
|
N/A |